Showing 4951-4960 of 5957 results for "".
- Wayne State Researchers Identify Cornea as a Potential Carrier of COVID-19https://modernod.com/news/wayne-state-researchers-identify-cornea-as-a-potential-carrier-of-covid-19/2478580/Scientists in the Department of Ophthalmology, Visual and Anatomical Sciences at the Wayne State University School of Medicine in Detroit have revealed that COVID-19 patients might harbor the virus in their eyes, demanding screening of ocular tissues before transplant surgeries during the pandemi
- Data Confirm Immune Response From AstraZeneca’s COVID-19 Vaccine in Elderlyhttps://modernod.com/news/data-confirm-immune-response-from-astrazenecas-covid-19-vaccine-in-elderly/2478582/Study results published in The Lancet suggest that the chimpanzee adenovirus-vectored COVID-19 vaccine being developed by AstraZeneca and the University of Oxford is able to produce a strong immune response in older adults, whilst being better tolerated in this age group than compared wi
- CEO says Pfizer “Very Close” to Filing COVID-19 Vaccine for US Emergency Usehttps://modernod.com/news/ceo-says-pfizer-very-close-to-filing-covid-19-vaccine-for-us-emergency-use/2478573/Pfizer CEO Albert Bourla suggested Tuesday that an FDA emergency-use authorization (EUA) request for the coronavirus vaccine it is co-developing with BioNTech is imminent. “We are very close to submitting for an [EUA],” Bourla reportedly said at a STAT News summit, but he would not sp
- Pfizer, BioNTech’s COVID-19 Vaccine Shows 95% Efficacy Rate at Final Analysishttps://modernod.com/news/pfizer-biontechs-covid-19-vaccine-shows-95-efficacy-rate-at-final-analysis/2478571/Pfizer and BioNTech announced Wednesday that their mRNA-based COVID-19 vaccine candidate BNT162b2 demonstrated an efficacy rate of 95% at the final efficacy analysis of a phase 3 study. The companies noted the primary objective analysis is based on 170 cases of COVID-19, of which 162 cases were o
- Amazon Unveils Pharmacy Offering, Hitting Shares of Drug Retailershttps://modernod.com/news/amazon-unveils-pharmacy-offering-hitting-shares-of-drug-retailers/2478569/Amazon.com announced Tuesday the launch of Amazon Pharmacy, allowing customers in the US to complete an entire pharmacy transaction on their desktop or mobile device through the Amazon app. The move sent shares in other drug retailers down, with Walgreens Boots falling over 11%, CVS Health slippi
- Alcon Canada Introduces AcrySof IQ Vivity Presbyopia-Correcting IOLhttps://modernod.com/news/alcon-canada-introduces-acrysof-iq-vivity-presbyopia-correcting-iol/2478568/Alcon has announced the Canadian launch of AcrySof IQ Vivity presbyopia-correcting IOL. AcrySof IQ Vivity uses a non-diffractive design called X-WAVE technology and provides an extended range of vision and reduced dependency on glasses following cataract surgery.
- IRIS Registry Reveals Insights into Eye Disease Prevention and Treatmenthttps://modernod.com/news/worlds-largest-specialty-clinical-data-registry-reveals-insights-into-eye-disease-prevention-and-treatment/2478566/The IRIS Registry powered a number of big data studies this year, many of which were presented at AAO 2020 Virtual, the 124th annual meeting of the American Academy of Ophthalmology. The research findings are now available to view on demand. “With a growing pool of aggregated d
- Topcon Announces Launch of Chronos Binocular Refraction Systemhttps://modernod.com/news/topcon-announces-the-us-launch-of-chronos/2478562/Topcon Healthcare announced that it has launched the Chronos Automated Binocular Refraction System with SightPilot guided refraction software. Topcon Chronos is a digital refraction solution that combines autorefraction, keratometry, and subjective refraction in a single device that occupi
- Innovent Announces the Results of the Phase 1 Clinical Trial of IBI302 for Wet AMD at AAO 2020https://modernod.com/news/innovent-announces-the-results-of-the-phase-1-clinical-trial-of-ibi302-for-wet-amd-at-aao-2020/2478560/Innovent Biologics announces that the results of the phase 1 clinical trial of IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein for wet age-related macular degeneration (AMD) is released in e-poster at 2020 American Academy of Ophthalm
- Kodiak Sciences Completes Enrollment of Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet AMDhttps://modernod.com/news/kodiak-sciences-completes-enrollment-of-phase-2b-3-pivotal-study-of-ksi-301-in-patients-with-wet-amd/2478561/Kodiak Sciences announced that recruitment has concluded in its DAZZLE pivotal study of KSI-301, Kodiak’s anti-VEGF antibody biopolymer conjugate, in patients with wet age-related macular degeneration (AMD). DAZZLE was planned to enroll 550 treatment-naïve patients worldwide; the target enr